Market Cap: $3.91B
AI
AbCellera Biologics Inc.
ABCL
NASDAQ (NASDAQ Global Select)USD
Market Cap: $3.91B
AbCellera Biologics Advances Antibody Discovery at Investor Conferences AbCellera Biologics, a Vancouver-based leader in antibody medicine development, actively engages the investment community by par…
AbCellera Biologics Prepares for 2024 Financial Results Announcement AbCellera Biologics, a Vancouver-based biotechnology company, is gearing up to unveil its full-year financial results for 2024 on F…
Innovative Approaches in Antibody Discovery at AbCellera Biologics AbCellera Biologics, a Vancouver-based biotechnology firm, stands out in the competitive landscape of antibody medicine development.…
AbCellera Biologics: Pioneering Antibody Discovery and Development AbCellera Biologics Inc, a Vancouver-based biotechnology company, is at the forefront of antibody medicine discovery and development,…
AbCellera Biologics Advances T-Cell Engager Platform to Combat Solid Tumors AbCellera Biologics is making significant strides in the fight against solid tumors with the presentation of new data on its…
AbCellera Biologics Advances T-Cell Engager Technology for Solid Tumors AbCellera Biologics, a leader in antibody discovery, recently presents groundbreaking data on its T-cell engager (TCE) platform…
AbCellera Biologics Achieves Milestones in Collaboration and Clinical Advancements AbCellera Biologics marks a significant milestone in its operational strategy as it reports a 13% increase in partner…
AbCellera Biologics: Progress in Clinical Advancements and Infrastructure Development AbCellera Biologics, a leader in the biotech sector, showcases notable advancements in its operations and collabor…